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Kinases use ATP to phosphorylate substrates;
recent findings underscore the additional regulatory
roles of ATP. Here, we propose a mechanism for
allosteric regulation of Akt1 kinase phosphorylation
by ATP. Our 4.7-ms molecular dynamics simulations
of Akt1 and its mutants in the ATP/ADP bound/
unbound states revealed that ATP occupancy of
the ATP-binding site stabilizes the closed confor-
mation, allosterically protecting pT308 by restrain-
ing phosphatase access and key interconnected
residues on the ATP/pT308 allosteric pathway.
Following ATP/ADP hydrolysis, pT308 is exposed
and readily dephosphorylated. Site-directed muta-
genesis validated these predictions and indicated
that the mutations do not impair PDK1 and PP2A
phosphatase recruitment. We further probed the
function of residues around pT308 at the atomic
level, and predicted and experimentally confirmed
that Akt1H194R/R273H double mutant rescues pathol-
ogy-related Akt1R273H. Analysis of classical Akt ho-
mologs suggests that this mechanism can provide
a general model of allosteric kinase regulation by
ATP; as such, it offers a potential avenue for allo-
steric drug discovery.
INTRODUCTION
As a ubiquitously expressed serine/threonine protein kinase, Akt
(also known as protein kinase B, or PKB) constitutes a central
node in signaling cascades and plays a pivotal role as a signal
transducer downstream of activated phosphoinositide 3-kinase
(PI3K) (Franke et al., 1995; Vivanco and Sawyers, 2002). In
mammalian cells, Akt is encoded by three highly homologous
isoforms (sequence similarity >90%), designated as Akt1, Akt2
and Akt3, which are activated via a multi-step process. Akt acti-Structure 23, 1725–17vation is initiated by recruitment to the plasma membrane
through the interaction of its pleckstrin homology (PH) domain
with phosphatidylinositol-3,4,5-triphosphate (PIP3), the product
of PI3K generated upon insulin stimulation (Woodgett, 2005),
or phosphatidylinositol-3,4-bisphosphate (PIP2) (Dannemann
et al., 2010). At the plasma membrane, T308 in the activation
loop of the Akt1 kinase domain is phosphorylated by phosphoi-
nositide-dependent kinase 1 (PDK1) (Manning and Cantley,
2007). Phosphorylation of the activation loop is critical for regu-
lation of Akt activity. Phosphorylation of a second site at the
C-terminal hydrophobic motif (S473) by mTORC2 (mammalian
target of rapamycin complex 2) is required for maximal activation
(Sarbassov et al., 2005). Dephosphorylation by protein phospha-
tase 2A (PP2A) abrogates Akt activity (Liao and Huang, 2010).
Activated Akt phosphorylates downstream targets to exert
normal cellular functions, including cell survival, growth, prolifer-
ation, metabolism, migration, and angiogenesis (Cross et al.,
1995; Datta et al., 1997). Consistent with its diverse roles,
gain-of-function mutations are linked to cancer in humans,
whereas loss-of-function mutations cause insulin resistance
and diabetes (Manning and Cantley, 2007; Humphrey and
James, 2013). Akt2-deficient mice eradicate insulin-dependent
signaling in liver and skeletal muscle cells, deregulating glucose
homeostasis, which results in insulin resistance (Cho et al.,
2001). An inherited inactivating missense mutation R274H in
the catalytic loop of the Akt2 kinase domain is linked to auto-
somal-dominant severe insulin resistance and diabetes mellitus
in humans (George et al., 2004). Likewise, knockdown of PI3K-
C2a expression and subsequent reduction of Akt1 activity in
pancreatic b cells impairs glucose-stimulated insulin release
(Leibiger et al., 2010). Since downregulating Akt is implicated
in disease, many efforts have focused on uncovering Akt regula-
tion and drug discovery (Arencibia et al., 2013).
Structurally, the architecture of the Akt kinase domain consists
of two lobes (Figure 1): a smaller N-terminal lobe and a larger
C-terminal lobe. ATP is bound in a deep cleft between them,
located beneath a highly conserved glycine-rich nucleotide posi-
tioning motif, also called the G loop. In Akt1, the binding cleft of
ATP locates approximately 20 A˚ from the phosphorylated T308
(pT308) in the activation loop, which is encapsulated by three34, September 1, 2015 ª2015 Elsevier Ltd All rights reserved 1725
Figure 1. The Architecture of Akt1
(A) Surface representation of the activated Akt1 kinase domain (PDB: 4EKK) illustrating the surface locations of the N lobe (pink), G loop (green), activation loop
(cyan), and C lobe (light blue). The locations of ATP in the ATP-binding site and pT308 in the activation loop are displayed.
(B) Domain structure of Akt1. The kinase domain is in the central region of the molecule. The pleckstrin homology (PH) domain acts as phosphoinositide-binding
module, and the hydrophobic motif (HM) is located at the C terminus adjacent to the kinase domain.
(C) The Kabsch-Sander secondary structure cartoon of the Akt1 kinase domain. The purple solid arrows represent b strands, the red solid cylinders represent
a helices, and the gray solid cylinders represent loops.positively charged residues in the catalytic cleft: H194, R273,
and K297. Phosphorylation of T308 acts as an ‘‘on’’ switch for
Akt1 phosphorylation of its downstream substrates.
ATP occupancy of the ATP-binding cleft in Akt1 protects the
pT308 level (Chan et al., 2011; Lin et al., 2012). Conversely,
occupancy by ADP or the unbound state (apo) wasmarkedly inef-
fective inmaintaining the pT308 level. ATP-loaded pT308 resisted
dephosphorylation by PP2A. This ‘‘on-off’’ switch model via ATP
binding to Akt1 is important, since the universal function of ATP
in protein kinases is to provide the g-phosphate donor to phos-
phorylate substrates. In three-dimensional (3D) space, ATP is
distant frompT308with nodirect interaction (Figure 1), suggesting
allosteric communication from ATP in its binding cleft to pT308 in
the catalytic cleft. However, the mechanism has been elusive.
Here, based on a total of 4.7-ms explicit solvent molecular
dynamics (MD) simulations of Akt1 in the ATP/ADP bound/un-
bound states and its mutants, as well as experimental site-
directed mutagenesis, we propose the molecular mechanism
of ATP-dependent allosteric protection of pT308. Our results
show that ATP binding allosterically protects the pT308 site by
stabilizing the closed conformation of the Akt1 kinase domain,
which can restrict phosphatase access. We observe that the
allosteric pathway from ATP to the pT308 is connected by four
residues, which is confirmed by site-directed mutagenesis. In
contrast, in the ADP-bound or apo states, Akt1 is in its open
conformation, which disrupts the allosteric, ATP-dependent pro-
tective pathway, thereby exposing pT308 from the catalytic cleft,
making it accessible to phosphatase. Building on our resolved
mechanism, we next explore the disease-related R273H muta-
tion in the Akt1 kinase domain. Large-scale in silico screening
of Akt1 mutants predicted that the H194R mutation can alloste-
rically restore pT308 protection to the loss-of-function R273H1726 Structure 23, 1725–1734, September 1, 2015 ª2015 Elsevier Ltmutant. The R273H/H194R double mutant was tested experi-
mentally and observed to restore shielding of the phosphate
moiety of pT308. Collectively, our data suggest a new model of
Akt kinase regulation; together with the identified hotspots at
the atomistic level along the ATP to pT308 allosteric pathway,
it offers a path in therapy.
RESULTS
ATP Binding Protects the pT308 Site by Stabilizing the
Closed Conformation of the Akt1 Kinase Domain, in
Contrast to ADP Binding or the Apo Form
To identify the determinants of the molecular mechanism of Akt1
in the apo, ADP-bound, and ATP-bound states at the atomic
level, a comparative analysis was first carried out using MD sim-
ulations (Bucher et al., 2011; Henzler-Wildman and Kern, 2007;
Afanasyeva et al., 2014). To delineate Akt1 conformations in
the different states, the probability distributions for two atom-
pairs distances, one defined by the distance between the Ca
atoms of H194 in helix C of the N lobe and pT308 in the activation
loop of the C lobe (d1), and the other between the Ca atoms of
T160 in the tip of the G loop and G294 in the DFG loop (d2),
were calculated and converted into surface plots representing
the energy landscapes (Text S1). Comparison of the energy land-
scapes of Akt1 in the different states indicated that the simula-
tions were capable of capturing the population shifts between
the apo, ADP-bound, and ATP-bound Akt1 (Figure S1). Cluster
analysis (Text S1) of each MD trajectory further revealed that
upon binding ATP, the N and C lobes of the Akt1 kinase domain
were in a closed conformation, whereas in the ADP-bound or
apo states the two lobeswere in an open conformation (Figure 2).
This difference was characterized by the distance between H194d All rights reserved
Figure 2. Conformational Analysis of Akt1 in
the apo, ADP-Bound, andATP-BoundStates
The most representative structure for Akt1 in the
apo (top), ADP-bound (middle), and ATP-bound
(bottom) states obtained using cluster analysis
from 200 ns of MD simulations. The surface of Akt1
is displayed by electrostatic potentials: positive
charges are in blue, negative charges are in
red, and neutral charges are in white. Details of
interactions of ATP in the ATP-binding site and
pT308 in the catalytic cleft for the three simulated
systems are enlarged on the left- and right-hand
side, respectively. The G and DFG loops are
colored cyan, and salt bridges or H bonds are
depicted by green dotted lines. See also Figures
S1 and S2.and pT308, which was 10.6 ± 0.4 A˚ in the ATP-bound state
compared with 12.1 ± 0.6 A˚ in the ADP-bound state and 12.6 ±
1.0 A˚ in the apo state (Figure S2). In the ATP-binding cleft of
the ATP-bound Akt1 (Figure 2, bottom), the hydroxyl group
side chain of T160 formed a hydrogen bond (H bond) with the
g-phosphate moiety of ATP. Concomitantly, the phosphate moi-
ety of pT308 in the activation loop was surrounded by the cata-
lytic cleft residues H194, R273, and K297. In contrast, in the
ADP-bound (Figure 2, middle) or apo states (Figure 2, top), the
H bond between T160 and ADPwas lost, accompanied by expo-
sure of the phosphate moiety of pT308 from the catalytic cleft.
These data suggest that ATP occupancy of its binding cleft sta-
bilizes the closed conformational state of the Akt1 kinase
domain, and shields pT308 in the catalytic cleft against phospha-
tase attack. Conversely, the open conformational state of Akt1
kinase domain in the ADP-bound or apo states could render
the pT308 accessible to dephosphorylation.
To further determine the role of the closed conformation
of Akt1 kinase domain in the ATP-dependent protection
of pT308, we analyzed the trajectory of the wild-type (WT)
ATP-bound Akt1 kinase domain and found that two pairs of
salt bridges, K179/E198 and R200/E298, were maintained
with >80% occupancy between the N and C lobes of Akt1. MD
simulations of three ATP-bound Akt1 mutants, E198A, R200A,
and E298A, were further performed to explore the effects of
these mutations on the conformations of Akt1 (K179 was not
mutated due to its interaction with the ATP a/b-phosphate moi-
eties; mutating K179 would affect ATP binding). All mutationsStructure 23, 1725–1734, September 1, 2015increased the distance between H194
and pT308 by approximately 12%
compared with the WT. The solvent-
accessible surface area (SASA) of pT308
in the E198A, R200A, and E298A mutants
increased by approximately 28%, 42%,
and 25%, respectively, compared with
the WT. These data suggested that in all
three mutants the two lobes of the kinase
domain were in open conformation, with
the pT308 phosphate moiety at the cata-
lytic cleft exposed, which may enable
pT308 dephosphorylation by phospha-
tases. The simulations further indicatedthat the closed conformation of the kinase domain tethered by
these electrostatic interactions could be instrumental in the
ATP-dependent protection of pT308. To validate this model,
the three mutants were constructed in HeLa cells and tested
for pT308 levels. As shown in Figure 3A, these mutants promi-
nently diminished the pT308 levels compared with WT Akt1.
Collectively, these results suggested that formation of the closed
conformation of the Akt1 kinase domain is a prerequisite for ATP
to exert allosteric protection of the pT308 site.
The Molecular Basis of the Allosteric Communication
from ATP to pT308
ATP is 20 A˚ away from pT308, and no direct interactions exist
between them (Figure 1). To uncover the mechanism of signal
propagation, we sought to identify residues in the allosteric
communication from ATP in the ATP-binding cleft to pT308
in the catalytic cleft. The allosteric communication in the ATP-
bound Akt1 was explored via our in-house method (Text S1)
based on the Markov propagation analysis method developed
by Chennubhotla and Bahar (2006) and the NetworkView
method (Text S1) developed by Eargle and Luthey-Schulten
(2012). Using the two methods, the optimal allosteric pathway
from ATP to pT308 was identified as follows (Text S1; Figure S3)
ATP/T160/F161/E191/H194/pT308:
Four residues located in the G loop (T160 and F161) and helix
aC (E191 andH194) were found to be involved in propagating theª2015 Elsevier Ltd All rights reserved 1727
Figure 3. ATP-Dependent Allosteric
Communication from ATP to pT308
(A) Effects of T160A, F161A, E191A, H194R,
E198A, R200A, K297A, and E298A mutants on
phosphorylated Akt1. MyrAkt1 (myristoylated
Akt1) and Akt1 mutants were transfected into
HeLa cells. After 48 hr, cells were lysed for western
blots. MyrAkt1, pT308-MyrAkt1, and GAPDH were
analyzed by immunoblotting (upper panel). An
unpaired (equal variance) t test was performed on
the relative levels of pT308 in eachMyrAkt1 mutant
compared with that of MyrAkt1 wild-type (WT)
(lower panel) (n = 3; **p < 0.01).
(B) The signal propagation pathway from ATP to
pT308 in the ATP-bound Akt1.
(C) Schematic representation of the interactions of
residue 191 with F161 and H194 in the WT, E191A,
E191G, E191L, E191H, and E191W mutants. The
generated steric hindrances in the E191L, E191H,
and E191W mutants are colored red.
(D) Effects of E191G, E191A, E191L, E191H, and
E191W mutants on phosphorylated Akt1. MyrAkt1
and mutants in both (A) and (D) were transfected
into HeLa cells for 48 hr followed by immunoblot
analysis of Akt1 T308 phosphorylation and HA-
tagged MyrAkt1 expression.
See also Figures S3–S5.signal from ATP to pT308 (Figure 3B). Alteration of the residues
could then interrupt the propagation. Indeed, the H194A mutant
abolishes ATP-dependent resistance to dephosphorylation
(Chan et al., 2011). Inspired by this finding, we investigated
the effects of T160, F161, and E191 on the allosteric pathway
by mutagenesis in HeLa cells. As shown in Figure 3A, the
T160A and F161A mutants reduced the pT308 level compared
with WT Akt1, indicative of their involvements in the allosteric
communication. Surprisingly, the E191A mutant showed a
2-fold increase of the pT308 level compared with WT Akt1. To
unveil the unexpected change the conformational effect of
E191 in the allosteric pathway was analyzed, and the result
showed that the side-chain carboxyl group of E191 was
H-bonded to the imidazole ring of H194, which, in turn, donated
anHbond to thephosphatemoiety of pT308 (Figure 3B). Presum-
ably, theHbond fromE191 drawsH194 toweaken the protection
of pT308 by H194, which can promote the likelihood of phospha-
tase access. When E191 is mutated to alanine, A191 is compat-
ible with the cavity formed by F161 and H194 (Figure 3C) but the
mutual attraction between A191 and H194 decreases, and the
interaction between H194 and pT308 strengthens. The confor-
mational difference (Valley et al., 2012) is supportedby the energy
change of H194/pT308 calculated by the two-layer ONIOM-
based quantum mechanical/molecular mechanical method,
with the interaction energy in the E191A mutant approximately
3.2 kcal/mol lower than in the WT (Text S2). Taken together,
these data suggest that phosphatase resistance canbe sufficient
in the E191A mutant, more so than in the WT Akt1.
To further investigate the role of residue 191 side chain in the
allosteric pathway from ATP to pT308, four additional mutants,1728 Structure 23, 1725–1734, September 1, 2015 ª2015 Elsevier Ltd All rights reservedE191G, E191L, E191H, and E191W,
were constructed and tested. In the allo-
steric modeling, the lack of side chain inthe E191G mutant abrogates the allosteric signal propagation
from F161 to H194 (Figure 3C); larger volumes of side chains
such as L191, H191, and W191 are not compatible with the cav-
ity formed by F161 and H194 due to steric hindrance (Figure 3C).
As expected, the E191G mutant showed a significant decrease
in the pT308 level compared with WT Akt1 in our experimental
test (Figure 3D), which is in good agreement with the theoretical
model of allosteric communication from F161 to H194. In addi-
tion, protein expression of E191L, E191H, and E191W mutants
was significantly reduced, and these effects are likely derived
from structural instability due to steric conflicts. Thus, the com-
bination of theoretical and experimental data lends support to
the allosteric pathway from ATP to pT308, linking ATP binding
and pT308 protection.
Akt1 is a multi-domain kinase consisting of PH, kinase, and
hydrophobic motif (HM) domains (Wu et al., 2010). We observed
that the allosteric protection pathway is in theAkt1 kinasedomain
(residues 144–443). To evaluate the pathway, we expressed, pu-
rified, and investigated the activated WT human Akt1(144–443)
and its four mutants (T160A, F161A, E191A, and H194R), which
we observed to be involved in the allosteric pathway in vitro
(Wu et al., 2010; Kumar et al., 2001). We explored how the four
mutations affected the dephosphorylation of pT308 by PP2A.
The results showed that in the presence of ATP-g-S, T160A/
F161A/H194R mutants reduced the pT308 level compared with
WT Akt1(144–443) while the E191A mutant effectively increased
the resistance to T308 dephosphorylation (Figure S4), which is
in good agreement with our full-length Akt1 results in HeLa cells
(Figure 3A), suggesting that the identified allosteric pathway
plays a protective role in the independent kinase domain.
Figure 4. Design of a Rescue Protection of
pT308 in the Akt1 R273H Mutant
(A) Details of the intramolecular interactions of
pT308 with three residues in the catalytic cleft
(H194, H273, and K297) of the Akt1 R273H mutant
from 200 ns of MD simulation. The surface of
pT308 is depicted by dots, and green dotted lines
represent salt bridges or H bonds.
(B) Nearby residues including H194, K297, M306,
K307, C310, and Y326within a radius of 6 A˚ around
pT308 are displayed in the Akt1 R273H mutant.
(C) In silico mutagenesis analysis of pT308-
adjoining residues based on the Akt1 R273H
mutant. For each mutant, MD simulation was car-
ried out for 100 ns. The distances between the two
Ca atoms of residues in positions 194 and 308were
measured in each mutant.The Inability of the Akt1 R273H Mutant to Protect the
pT308 Site
ATP binding allosterically promotes the burial of the phosphate
moiety of pT308 in the catalytic cleft of Akt1 surrounded by
H194, R273, and K297, which can restrict phosphatase access.
These three residues can play a direct role in the protection of
pT308. In addition to the established effects of H194 and
R273, whose alanine mutants abolished the ATP-dependent
phosphatase resistance (Chan et al., 2011), we explored the
impact of K297 on the pT308 level. The results demonstrated
that the K297A mutant had only a slight effect (Figure 3A). This
indicated that both H194 and R273 act as dominant residues
in the catalytic cleft. Remarkably, a highly homologous R274H
in Akt2 (corresponding to R273 in Akt1) reported from diabetes
patients is an ATP-dependent phosphatase-resistant loss-
of-function mutant (George et al., 2004), similar to the Akt1
R273H mutant observed here (Figure 5A). Conformational anal-
ysis of the MD trajectories indicated that the pT308 phosphate
moiety lost salt bridges/H bonds with residues 194 and 273
(from 100% to 0%) when R273 was replaced by H273, and
was exposed from the catalytic cleft throughout the MD trajec-
tory (Figure 4A). This persistent exposure of pT308 may cause
its enhanced dephosphorylation by the phosphatase in the pa-
thology-related mutant.Structure 23, 1725–1734, September 1, 2015Akt1 H194R/R273H Double Mutant
Restores pT308 Site Protection
The results reported above revealed
that exposed pT308 failed to resist
dephosphorylation by phosphatase in
the pathology-related mutant, unlike
in the embedded protective state. To
confirm the hypothesis, we designed a
rescue strategy for pT308 in the Akt1
R273H mutant by enhancing the interac-
tions between other residues and pT308.
First, most of the residues in the vicinity
of pT308 including H194, K297, M306,
K307, C310, and Y326 (Figure 4B) were
respectively changed to H, K, Q, R, W,
andYbasedon theR273Hmutant, yielding
a total of 32 doublemutants in silico (TableS1). Then 100-ns MD simulations were performed on each to
investigate the effect of these substitutions on the protective
ability of pT308. Among these putative double mutants, only
the H194R mutation could decrease the distance between the
N and C lobes (Figure 4C) and the SASA of pT308 from 63.8%
to 24.1%, providing a significant potential recovery of the phos-
phatase resistance of pT308 of the double mutant. Finally, the
pT308 level of H194R/R273H double mutant was obtained and
comparedwith theWTAkt1. The results indicated that the double
mutant restored the WT pT308 level (Figure 5A). To avoid some
non-specific function by the additional H194R mutation, single
H194R and double H194R/R273S mutants were tested. Both
mutants were incapable of increasing the pT308 level in Akt1
on their own (Figure 5A), revealing the restoration by the addi-
tional H194R mutation in the R273H mutant.
To elucidate the reconstructed protection of pT308 in the
H194R/R273H double mutant, the H194R/R273HMD simulation
was extended to 200 ns and analyzed. As shown in Figure 5B,
the phosphate moiety of pT308 formed two salt bridges with
R194 and K297, and H273 formed an H bond with the backbone
carbonyl group of pT308. These intramolecular interactions
shielded the phosphate moiety of pT308 in the catalytic cleft,
stabilized thereby the closed conformation of the kinase domain
in the H194R/R273H double mutant, and rebuilt the allostericª2015 Elsevier Ltd All rights reserved 1729
Figure 5. Akt1 H194R/R273H Double Mutant Restores Protection of pT308 against Dephosphorylation
(A) Effects of H194R and R273H single mutants as well as H194R/R273H and H194R/R273S double mutants on phosphorylated Akt1. MyrAkt1 andmutants were
transfected into HeLa cells. After 48 hr, cells were lysed for western blots. MyrAkt1, pT308-MyrAkt1, andGAPDHwere analyzed by immunoblotting (upper panel).
An unpaired (equal variance) t test was performed on the relative levels of pT308 in each MyrAkt1 mutant compared with that of MyrAkt1-WT (lower panel) (n = 3;
*p < 0.05, **p < 0.01).
(B) Details of the intramolecular interactions of pT308 with three residues in the catalytic cleft (R194, H273, and K297) of the Akt1 H194R/R273H double mutant
from 200 ns of MD simulation. The surface of pT308 is depicted by dots, and green dotted lines represent salt bridges or H bonds.
(C) The signal propagation pathway from ATP to pT308 in the Akt1 H194R/R273H double mutant.
See also Figure S6.communication from ATP to pT308 in the H194R/R273H double
mutant (Figure 5C).
Mutations in Akt1 Do Not Impair Recruitment of PDK1
and PP2A
Akt is involved in the PI3K/Akt/mTOR pathway. Following growth
factor stimulation, activated PI3Ks catalyze the conversion of
PIP2 to PIP3, which directs the translocation of Akt to the plasma
membrane (Woodgett, 2005; Manning and Cantley, 2007). At the
membrane, T308 of Akt1 undergoes phosphorylation by PDK1.
To test whether the mutations in the allosteric pathway impair
the recruitment of PDK1 or phosphatase PP2A, the conse-
quences of Akt1 mutations (T160A, F161A, E191A, H194R, and
H194R/R273H) on pT308 levels were measured in the presence
of the PP2A inhibitor Calyculin A and PDK1 inhibitor BX-795. The
results showed that similar to changes in WT Akt1 (Figure 6A),
pT308 levels in all mutants were markedly increased in the pres-
ence of Calyculin A, which was counteracted by co-treatment
with BX-795 (Figure 6B). This result suggested that themutations
in Akt1 do not impair recruitment of PDK1 and PP2A.
DISCUSSION
ATP is generally used by protein kinases as the source of phos-
phate groups to phosphorylate their specific substrates. Recent
evidence indicates that ATP can also function as an allosteric
modulator (Huang et al., 2014; Lu et al., 2014a). Thus, under-
standing the allosteric mechanism of ATP in Akt1 may provide
broader insights into the role of ATP and its mechanism as an
endogenousmodulator in cell signaling and in an important class
of enzymes (Nussinov and Tsai, 2013; Lu et al., 2014b).1730 Structure 23, 1725–1734, September 1, 2015 ª2015 Elsevier LtCommunication between functional sites is central to protein
regulation. In most cases, the pathways through which the signal
propagates are poorly characterized (Goodey and Benkovic,
2008; del Sol et al., 2009; Lu et al., 2014c; Fetics et al., 2015).
Here, we show that protection of pT308 level by ATP depends
on formation of a finely tuned network of interactions within the
G loop and helix aC. Network and mutational analyses identified
four interconnected residues that directly communicate the ATP
signal to the pT308. These data are in accordancewith the notion
that a small subset of physically connected residues propagates
allosteric signals between distinct functional sites (Shen et al.,
2011; Guo et al., 2015; Datta et al., 2008). To determine the
specific pathway, we selected 12 additional residues in either
the PH or kinase domains of Akt1, mutated them to alanine,
and measured the pT308 levels of the mutants. These residues,
located approximately 3–30 A˚ away from the allosteric pathway,
were randomly selected on the surface of Akt1. As shown in Fig-
ure S5, the pT308 level of each mutant was almost the same as
that of WT Akt1, indicating the specificity of residues in the iden-
tified allosteric pathway.
The molecular mechanism of Akt1 unraveled ATP-dependent
allosteric signal propagation at the pT308 level, raising the pos-
sibility that allosteric communication could be a more general
mechanism for regulation of phosphorylation in other kinases.
To evaluate this possibility, several classical Akt1 kinase homo-
logs (similarity >40%), including cAMP-dependent protein ki-
nase (PKA) (Zheng et al., 1993), cyclin-dependent kinase 2
(CDK2), (Brown et al., 1999), TAO2 (Zhou et al., 2004), and
PDK1 (Biondi et al., 2002), were selected to analyze the poten-
tial allosteric communication from ATP to the respective phos-
phorylation sites in the activation loop by multiple sequenced All rights reserved
Figure 6. The Effect of MyrAkt1 Mutants in the Allsoteric Pathway for PDK1 and PP2A Recruitment
(A) Optimization of experimental conditions for two inhibitors in cells. HeLa cells were transfected with MyrAkt1-HA, and 48 hr after transfection the cells were
treated with different concentrations of BX-795 and Calyculin A for different times, respectively. MyrAkt1 T308 phosphorylation, HA-taggedMyrAkt1, and b-actin
were detected by immunoblotting.
(B) HeLa cells were transfected with MyrAkt1-HA mutants T160A, F161A, E191A, H194R, and H194R/R273H, and 48 hr after transfection cells were treated with
100 nM Calyculin A with or without 50 mM BX-795 for 1 hr. MyrAkt1 T308 phosphorylation (anti-pT308-Akt1), HA-tagged MyrAkt1 (anti-HA), and b-actin (anti-
b-actin) expression were detected by immunoblotting.alignment (Figure 7A). The results suggested that allosteric ki-
nase regulation by ATP is conserved in these kinases (Figures
7B–7D). In addition, the protective effect of endogenous ligand
binding has recently been described for a multi-subunit enzyme,
AMP-activated protein kinase (Xiao et al., 2013). Taken together,
in some kinases there is structural coupling between endoge-
nous ligands and phosphorylation sites. Along similar lines, an
‘‘on-off’’ allosteric regulation by post-translational modifications
is an established mode of regulation of dynamic signal transduc-
tion (Nussinov et al., 2012).
MD simulations and mutagenesis data revealed that Akt1
R273H mutation can result in dephosphorylation of pT308 by
phosphatase, whereas the Akt1 H194R/R273H double mutant
is able to rescue the pT308 level. These findings reflect the
electrostatic potential of R194 in protecting pT308. Arginine is
observed in corresponding positions in some homologous ki-
nases such as CDK2 (Brown et al., 1999) and p38g (Bellon
et al., 1999). Crystal structures of CDK2 and p38g demonstrate
that in their phosphorylated states the arginine residue (R50 for
CDK2 and R73 for p38g) forms direct electrostatic interactions
with the phosphorylated threonine of the two kinases, suggest-
ing an active role for R194 in the protection of Akt1 phosphory-
lation. An opposite effect was observed for the WT and the
R273H mutant in Akt1 (Figure 5A). Conformational analysis of
the MD trajectory revealed that R194 in the Akt1 H194R mutant
lost salt bridges with the phosphate moiety of pT308 due to
spatial mismatch, resulting in pT308 exposure from the catalytic
cleft throughout the H194R simulation (Figure S6), which could
cause dephosphorylation of pT308 (Figure 5A). By contrast, inStructure 23, 1725–17the H194R/R273H double mutant, R194 perfectly reconstructed
the exquisite network of pT308 that shielded the phosphate moi-
ety of pT308 (Figure 5). Collectively, these data suggest that both
a positive electrostatic group and a structural match are impor-
tant in the protection of pT308 in the Akt1 catalytic cleft. Recov-
ery of phosphatase resistance of pT308 in the Akt1 R273H
mutant by H194R could suggest new anti-diabetes strategies,
or an allosteric drug mimicking this effect. Shearn et al. (2011)
reported that modification of a crucial histidine by 4-hydroxy-
2-nonenal in the catalytic cleft of Akt is able to inhibit insulin-
dependent Akt signaling in HepG2 cells.
To conclude, our MD simulations of Akt1 in different states
coupled with experiments unraveled the mechanism of allosteric
regulation of Akt1 phosphorylation by ATP on the conformational
level, and elucidated the function of a disease-related mutant
and its rescue. Our analysis suggests that this regulation mech-
anismmay hold for additional members of the Akt family. Finally,
covalent modification of H194 in Akt1 R273H mutant may pro-
tect pT308, and constitute a covalent allosteric drug discovery
rescue strategy for Akt2 R274H patients (Nussinov and Tsai,
2015).
EXPERIMENTAL PROCEDURES
Simulation Systems
The initial structure of Akt1 kinase domain in complex with the non-hydro-
lyzable ATP analog adenylyl imidodiphosphate (AMP-PNP), Mg2+, and
GSK3b-derived peptide was extracted from the PDB entry PDB: 4EKK (Lin
et al., 2012). AMP-PNP was replaced by the physiological ATP to represent
the ATP-bound Akt1 complex. The ADP-bound Akt1 complex was then34, September 1, 2015 ª2015 Elsevier Ltd All rights reserved 1731
Figure 7. The Potential Allosteric Communi-
cation from ATP to the Respective Phos-
phorylation Sites in Other Kinases
(A) Multiple sequence alignment of the amino
acids in the kinase domains of Akt1, PKA, CDK2,
TAO2, and PDK1. This alignment was produced by
the ClustalX2 program. Only representative se-
quences located in the allosteric pathway and
in the catalytic cleft are shown. Residues in the
allosteric pathway in this study are indicated by
asterisks. The listed residue numbers refer to Akt1.
Identical residues are marked dark cyan; similarity
is indicated by light cyan.
(B) The signal propagation pathway from ATP to
pT197 in PKA (PDB: 1ATP).
(C) The signal propagation pathway from ATP to
pT160 in CDK2 (PDB: 1QMZ).
(D) The signal propagation pathway from ATP to
pS181 in TAO2 (PDB: 1U5R).
(E) The signal propagation pathway from ATP to
pS241 in PDK1 (PDB: 4AW0).constructed by removing the g-phosphoryl moiety of ATP, while the apo state
was obtained by removing ATP from the active site. Akt1 mutants were con-
structed with the biopolymers module of SYBYL (Tripos Associates).
3D-RISM Calculation and Placevent Algorithm
The 3D reference interaction site model (3D-RISM) theory is an integral equa-
tion theory based on statistical mechanics (Imai et al., 2009), which generates
accurate 3D solvent distribution function of water molecules around and inside
a biomolecule of interest. The Placevent algorithm (Sindhikara et al., 2012) was
then exploited to translate the continuous distributions from the 3D-RISM
calculation to explicit water molecules. The detailed 3D-RISM calculation
and Placevent algorithm are provided in Text S1. Based on the 3D-RISM and
Placevent calculations, including the Placevent-predicted water molecules in
the ATP-bound Akt1 complex is preferred (as compared with without Place-
vent-predicted water molecules) in reproducing the Akt1 active-site crystallo-
graphic architecture. Therefore, in the apo, ADP- and ATP-bound Akt1, as
well as in all Akt1 mutants, we employed the corresponding initial models in
complexwith the Placevent-predictedwatermolecules for theMDsimulations.
MD Simulations
MD simulations were performed with the AMBER 11 package (Case et al.,
2005). Computation of the protonation state of titratable groups at pH 7.0
was carried out using the H++ web server (Gordon et al., 2005). The AMBER
ff03 (Duan et al., 2003) force field was assigned for the protein. The parameters
for ADP, ATP, and pT308 were taken from the AMBER parameter database.1732 Structure 23, 1725–1734, September 1, 2015 ª2015 Elsevier Ltd All rights reservedThe starting protein complexes were explicitly sol-
vated by TIP3P water molecules in the truncated
octahedral box, where the distance to the edge of
the solvent box from protein was set to be 10 A˚.
Counterions were added to maintain the electro-
neutrality of these systems. In total, 4.7-msMD sim-
ulations of Akt1 in ATP/ADP bound/unbound and
itsmutants (TableS1)wereperformed.Thedetailed
MD procedures are provided in Text S1.
Cell Culture, Plasmids, and Antibodies
HeLa cells were cultured in DMEM supplemented
with 10% FBS, and 1% penicillin/streptomycin.
Cells were maintained at 37C under 5% CO2.
Myristoylated Akt1 from pCMV6-Myr-Akt1 was
subcloned into the vector pEF-3HA to obtain
the construct pEF-Myr-Akt1-HA (MyrAkt1) (Wang
et al., 2000). All mutant constructs were generated
by site-directed mutagenesis employing a PCR-based strategy according to the KOD-Plus-mutagenesis Kit protocol (Toyobo).
Twenty-seven mutants (T160A, F161A, E191A, E191G, E191L, E191H,
E191W, H194R, E198A, R200A, R273H, K297A, E298A, T101A, T105A,
N199A, S216A, F236A, D262A, E278A, K301A, E355A, G373A, S381A,
Y417A, R273H + H194R, R273S + H194R) were constructed, and the mutation
sites and primers of Akt1 are listed in Table S2. Antibodies anti-Akt1 (2H10),
anti-pT308-Akt1 (#9275), and anti-b-actin (13 3 105) were from Cell Signaling
Technology; anti-PP2A-C (#05-421) was from Millipore; anti-His-tag (#66005-
1-Ig) was from Proteintech; anti-GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase) was from Sungene Biotechnology; and anti-HA-tag (16B12) was
from Covance.
In-Culture Phosphorylated T308 Level of MyrAkt1 and Its Mutants
HeLa cells were transiently transfected with 4 mg of each plasmid (WT or
mutated pEF-Myr-Akt1-HA) using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s protocols. After 48 hr, cells were lysed in SDS buffer
(62.5 mM Tris-HCl, 2% SDS [pH 6.8]) and boiled for 10 min. Usually 200 mg
of each lysate was subjected to 10% SDS-PAGE. For western blotting
analysis, the primary antibodies anti-Akt1 (2H10), anti-pT308-Akt1 (Cell
Signaling Technology), and anti-GAPDH (Sungene Biotechnology) were used
at a 1:1,000 dilution in TBST buffer containing 5% BSA.
In-Culture Dephosphorylation of MyrAkt1 and Its Mutants
HeLa cells were transfected with plasmid of MyrAkt1 (or its mutants) as
described above. After 48 hr of transfection, inhibitors (Calyculin A or Calyculin
A + BX-795) were added to medium and incubated at 37C for 1 hr, then cells
were lysed and dephosphorylation of MyrAkt1 (or its mutants) was analyzed by
western blotting as previously described (Chan et al., 2011).
Expression and Purification of Akt1(144–443) Proteins
Human Akt1(144–443) protein and its four mutants T160A, F161A, E191A, and
H194R were expressed in Sf9 cells (Invitrogen) with an N-terminal hexahisti-
dine (His) tag, and purified in vitro using the general protocol described previ-
ously (Kumar et al., 2001; Wu et al., 2010). The proteins were enriched from the
Sf9 cell lysate on Ni-NTA Agarose (Qiagen), then eluted from the Ni beads in a
buffer consisting of 25 mM Tris-HCl (pH 8.0), 0.3 M NaCl, 0.05% (v/v) 2-mer-
captoethanol, 100 mM imidazole, 10% (v/v) glycerol, and Complete EDTA-
free protease inhibitor (Roche). The proteins were further purified via Superdex
200 size-exclusion chromatography (GE Health Biosciences) using the final
storage buffer of 25 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10% glycerol, and
5 mM DTT. All purification steps were performed at 4C and the final proteins
were stored at 80C.
In Vitro Phosphorylation of Akt1(144–443) and Its Mutants
PDK1 (Active Motif) was used to phosphorylate Akt1(144–443) protein and its
four mutants for activation in vitro according to the manufacturer’s protocol.
14 mg of Akt1(144–443) protein (or each mutant) was added to a 50-ml solution
of 50mMTris-HCl (pH 7.5), 0.1mMEDTA, 2mMDTT, 10mMMgCl2 containing
0.7 mg of PDK1, and 100 mM ATP (Sigma). The mixture was incubated for
30 min at 30C and the remaining ATP in solution was removed using Probe-
Quant G-50 Micro Columns (GE Healthcare) for further dephosphorylation
assay.
In Vitro Dephosphorylation of Akt1(144–443) and Its Mutants by
PP2A-C
Phosphorylated Akt1(144–443) protein and its four mutants were dephos-
phorylated in vitro by PP2A-C according to the manufacturer’s protocol. To
assess the effect of ATP-g-S (Biolog) on the dephosphorylation, phosphory-
lated Akt1(144–443) protein (or each mutant) was aliquoted and pre-incubated
with or without 500 mM ATP-g-S for 10 min at 30C in phosphatase assay
buffer (50 mM HEPES [pH 7.5], 100 mM NaCl, 1 mM DTT, 10 mM MgCl2),
then 80 ng of PP2A-C was added and incubated for 50 min at 30C in a
final volume of 30 ml. Phosphatase reactions were terminatedwith SDS sample
buffer, and Akt1 T308 phosphorylation (anti-pT308-Akt1), total His-Akt1 (144–
443) (anti-His), and PP2A-C (anti-PP2A-C) were analyzed by immunoblots.
Statistical Analysis
Quantitation was analyzed by ImageJ v1.46 (NIH), and the relative intensity of
the Akt1 pT308 band was normalized to the corresponding total Akt1. For all
bar plots, the quantitative data were presented as means ± SD of three inde-
pendent measurements. The statistical significance of compared measure-
ments was evaluated using the two-tailed unpaired Student’s t test, and a p
value of <0.05 (*) or <0.01 (**) was considered statistically significant.
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